ReviewCancers2023
Cancer-Associated Fibroblasts: Master Tumor Microenvironment Modifiers.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 148 citations in OpenAlex.
- Compartment-Specific Immunohistochemical Alterations Along the Colorectal Adenoma-Carcinoma Continuum.Digestive diseases and sciences · 2026Article
- Rewiring the tumor microenvironment: IGFBP2 at the Nexus of remodeling and therapy resistance?Biochimica et biophysica acta. Reviews on cancer · 2026Review
- Nanoparticle delivery of Chinese medicine monomers for remodeling the colorectal cancer immune microenvironment.Discover nano · 2026Review
- Molecular cartography of breast cancer: decoding genomes, heterogeneity and the tumor microenvironment for personalized targeted therapeutics.Molecular biology reports · 2026Review
- Label-Free Monitoring of Cancer-Associated Fibroblast Activation Using NAD(P)H Fluorescence Lifetime Imaging.Chembiochem : a European journal of chemical biology · 2026Article
- Article
- Cancer-associated fibroblasts in thyroid cancer stroma correlate with tumour progression and desmoplasia: a histopathological study.Thyroid research · 2026Article
- Diosmetin Modulates EMT-Associated Plasticity and Fibroblast-Activation Markers in Parallel Breast Cancer In Vitro Models.Molecules (Basel, Switzerland) · 2026Article
- The role of ECM mechanics in cancer mechanotransduction through unraveling the molecular machinery of integrins, FAK, and YAP signaling.Cellular & molecular biology letters · 2026Review
- Combined fat and sugar intake reshapes the tumor microenvironment through hypoxia and lipogenic pathways in breast cancer.European journal of nutrition · 2026Article
- Oxidative stress and serum deprivation influence the evolution of newly formed tetraploid cells during tumorigenesis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- NF-κB activation and cytokine dysregulation: a pathogenic loop in breast cancer inflammation - a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Serum levels of immunoglobulins, tumour markers, and chemokines in gastric cancer patients treated with SOX regimen versus oxaliplatin monotherapy.Journal of medical biochemistry · 2026Article
- Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity.Nanoscale advances · 2026Review
- Modulatory effects of Pioglitazone on the CAF-driven malignant phenotype in cervical cancer: an in vitro bidirectional study.Discover oncology · 2026Article
- Fibromodulin positively regulated by Androgen Receptor, promotes prostate cancer progression via the PI3K/AKT signaling pathway and epithelial-medenchymal transition.Molecular biology reports · 2026Article
- Bidirectional Interactions Between Immune Regulation and the Insulin-like Growth Factor Axis in Colorectal Cancer.International journal of molecular sciences · 2026Review
- Targeting phase separation: a new strategy to disrupt the stromal-immune axis in colorectal cancer.Cell communication and signaling : CCS · 2026Review
- Decoding the spatiotemporal characteristics of ferroptosis: reshaping tumour therapeutic strategies.Experimental hematology & oncology · 2026Review
- Prostate‑specific membrane antigen: Molecular functions and emerging roles as a therapeutic target (Review).Molecular medicine reports · 2026Review
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Cancer cells rely on the tumor microenvironment (TME), a composite of non-malignant cells, and extracellular matrix (ECM), for survival, growth, and metastasis. The ECM contributes to the biomechanical properties of the surrounding tissue, in addition to providing signals for tissue development. Cancer-associated fibroblasts (CAFs) are stromal cells in the TME that are integral to cancer progression. Subtypes of CAFs across a variety of cancers have been revealed, and each play a different role in cancer progression or suppression. CAFs secrete signaling molecules and remodel the surrounding ECM by depositing its constituents as well as degrading enzymes. In cancer, a remodeled ECM can lead to tumor-promoting effects. Not only does the remodeled ECM promote growth and allow for easier metastasis, but it can also modulate the immune system. A better understanding of how CAFs remodel the ECM will likely yield novel therapeutic targets. In this review, we summarize the key factors secreted by CAFs that facilitate tumor progression, ECM remodeling, and immune suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.